



## Developing the next generation of immuno-oncology therapeutics

### RXI Pharmaceuticals Selected to Present at the Landmark Venture Forum

March 20, 2018

**The forum brings together leading family offices, high net worth private investors, pharma and foundations to explore the latest innovations from emerging and growth stage companies.**

MARLBOROUGH, Mass., March 20, 2018 /PRNewswire/ -- RXI Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform announced today that Dr. Geert Cauwenbergh, RXI's President and CEO, will present at the Landmark Venture Forum hosted by Landmark Angels.

**Date:** Tuesday, March 27, 2018  
**Time:** 10:10 a.m. EDT  
**Location:** Greenwich Hyatt Regency, Old Greenwich, Connecticut

Dr. Cauwenbergh will highlight the Company's sd-rxRNA® platform and the ongoing internal and external programs that leverage the self-delivering attributes of its therapeutic compounds in the development of cell-based therapies to treat cancer.

The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, [www.rxipharma.com](http://www.rxipharma.com), approximately 1 hour following the presentation.

#### About RXI Pharmaceuticals

RXI Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. Building on the pioneering discovery of RNAi, scientists at RXI have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXI developed a robust RNAi therapeutic platform, including sd-rxRNA compounds, that has the potential to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. RXI's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website, [www.rxipharma.com](http://www.rxipharma.com).

#### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcypnone™, RXI-762, RXI-804 and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXI's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXI does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

**Contact**  
RXI Pharmaceuticals Corporation  
Tamara McGrillen  
508-929-3646

View original content: <http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-selected-to-present-at-the-landmark-venture-forum-300616224.html>

SOURCE RXI Pharmaceuticals Corporation